{
  "_id": "4dbc024dde83fc9352823fe1967c6f82bcc9c43288ba02054ca4c49715b34600",
  "feed": "wall-street-journal",
  "title": "Johnson & Johnson Posts Higher Quarterly Sales Despite Strong Dollar; Healthcare-products firm trims full-year sales outlook after foreign-exchange reduced quarterly sales by 6%",
  "text": "<p>The company cut its full-year sales guidance to a range of $93 billion to $93.5 billion, excluding sales from the company's Covid-19 vaccine. In July, J&amp;J guided for full-year sales of $93.3 billion to $94.3 billion. J&amp;J narrowed its guidance for full-year operational sales, which also excludes the impact from currency-fluctuations, to a range of $97.5 billion to $98 billion. The company also narrowed its adjusted earnings guidance to a range of $10.02 a share to $10.07 a share. Shares of J&amp;J rose more than 2% in premarket trading to $170.19. So far this year, the stock was down almost 3% as of Monday's closing price. Write to Will Feuer at Will.Feuer@wsj.com</p><p>Johnson &amp; Johnson Posts Higher Quarterly Sales Despite Strong Dollar</p>",
  "published": "2022-10-18T11:07:00.000Z",
  "tags": [
    {
      "id": "US4781601046",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 151,
          "end": 154
        },
        {
          "start": 0,
          "end": 17
        },
        {
          "start": 494,
          "end": 497
        },
        {
          "start": 217,
          "end": 220
        },
        {
          "start": 668,
          "end": 685
        }
      ],
      "nexusId": "10010560"
    }
  ]
}